





Letter to the Editor

Cite this article: Hashmi FK, Atif N, Malik UR, et al. In pursuit of COVID-19 treatment strategies: Are we triggering antimicrobial resistance? *Disaster Med Public Health Prep.* doi: <https://doi.org/10.1017/dmp.2020.492>.

Corresponding author:
Tauqeer Hussain Mallhi,
Email: tauqeer.hussain.mallhi@hotmail.com.

In Pursuit of COVID-19 Treatment Strategies: Are We Triggering Antimicrobial Resistance?

Furqan Khurshid Hashmi PhD¹ , Naveel Atif MPhil² , Usman Rashid Malik MPhil¹, Fahad Saleem PhD³, Zineb Riboua MPP⁴, Mohamed Azmi Hassali PhD⁵, Muhammad Hammad Butt MPhil⁶ , Tauqeer Hussain Mallhi PhD⁷  and Yusra Habib Khan PhD⁷

¹Punjab University College of Pharmacy, University of the Punjab, Allama Iqbal Campus, Lahore, Pakistan; ²Center of Drug Safety and Policy Research, School of Pharmacy, Xi'an Jiaotong University, Xi'an, Shaanxi, China; ³Faculty of Pharmacy, University of Balochistan, Quetta, Balochistan, Pakistan; ⁴McCourt School of Public Policy, Georgetown University, Washington DC, USA; ⁵School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia; ⁶Faculty of Pharmacy, University of Central Punjab, Lahore, Punjab, Pakistan and ⁷Department of Clinical Pharmacy, College of Pharmacy, Jouf University, Kingdom of Saudi Arabia

Coronavirus disease 2019 (COVID-19) poses substantial challenges to social life and health-care systems across the world. Because there is no specific treatment against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), repurposing of antimicrobial agents remains a mainstay in managing COVID-19 patients. However, the expanded use of broad-spectrum antibiotics carries significant risks of antimicrobial resistance while managing COVID-19 patients. In this context, the World Health Organization (WHO) has recommended preventive and precautionary measures, such as social distancing, self-isolation, hand hygiene, and lockdowns, as effective disease containment modalities during the pandemic.^{1,2}

Existing data demonstrates that COVID-19 is associated with secondary infections, such as pulmonary pneumonia and ventilator-associated pneumonia.³ In the case of secondary infections, use of antimicrobials is the only treatment strategy left for physicians, especially for suspected bacterial infections.⁴ The crisis of antimicrobial resistance (AMR) is becoming devastating with each passing year, which has cautioned health-care providers to be judicious with the use of antimicrobial agents.^{5,6} The current COVID-19 pandemic threatens to further jeopardize the use of available antimicrobial agents as treatment strategies.

Following the H1N1 influenza outbreak in 2009, several environmental microbiologists warned that the excessive use of antibiotics might lead to an increase in resistant bacterial infections, while during the current COVID-19 pandemic, many cases were treated excessively with antibiotics.³ The majority of COVID-19 patients are either asymptomatic or may experience mild to moderate illness without bacterial infection.⁷ However, uncertainty among health-care professionals about the prudent use of antibiotics among COVID-19 patients is an intimidating factor in terms of additional health-care costs, especially for countries with limited resources and poor quality of health services.⁸ Unnecessary antibiotic use in viral diseases and epidemics is leading to an increased AMR and, thus, has amplified the financial burden.⁹ Because AMR has already been declared as a global emergency, health-care professionals need to be careful with the use of antimicrobial agents for the treatment of secondary infections that may arise during the course of COVID-19 and other viral diseases.

Implementation of antimicrobial stewardship programs (ASPs) has been associated with decreased antibiotic use and reduced costs,¹⁰ which ultimately reduces the AMR burden. WHO's interim guidelines on the clinical management of COVID-19 suggest the integration of ASPs in the health-care system. These guidelines have discouraged the use of antibiotics in mild or moderate COVID-19 patients without symptoms of a bacterial infection. However, antibiotics classified in WHO's AWaRe (access, watch, reserve) category, such as co-amoxicillin, could preferably be used in geriatrics and pediatrics.¹¹

Health-care authorities and professionals should take hard lines to implement and practice the WHO's guidelines during management of COVID-19 patients.¹² Prolonged stay of patients in hospitals resulting from secondary and super-infections may further put unnecessary strain on health-care systems. A multipronged approach using evidence-based practices should be considered for treatment of COVID-19 patients. In addition, compliance with the WHO's Global Action Plan on AMR is of utmost importance. This can help reduce the additional health-care costs and burden on overwhelmed health-care systems.

Periodic sensitivity testing will help to ascertain the pattern of prevailing AMR so that timely and effective combat strategies can be initiated. Pharmacists and other health-care professionals can play a pivotal role in implementation of ASPs to reduce the injudicious use of antimicrobials during the current COVID-19 pandemic. In a nutshell, appropriate ASP implementation and monitoring can help allocate resources to manage global public health crises effectually.

Author Contributions. All authors contributed equally in conceptualization, data retrieving, letter write up, and approved the final version of manuscript.

Conflict of Interest. Authors declare no competing conflict of interest.

References

1. **Misbah S, Ahmad A, Butt MH, et al.** A systematic analysis of studies on corona virus disease 19 (COVID-19) from viral emergence to treatment. *J Coll Physicians Surg Pak.* 2020;30(6):9–18.
2. **Mallhi TH, Ahmad A, Butt MH, et al.** Chloroquine and hydroxychloroquine in COVID-19: practice implications for healthcare professionals. *J Coll Physicians Surg Pak.* 2020;30(10):124–128.
3. **Zhou F, Yu T, Du R, et al.** Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet.* 2020;395(10229):1054–1062.
4. **Arthur LE, Kizor RS, Selim AG, et al.** Antibiotics for ventilator-associated pneumonia. *Cochrane Database Syst Rev.* 2016;10(10):CD004267.
5. **Park JJ, Murthy S.** Defining optimal empirical antibiotic regimens in a rapidly changing landscape of resistance. *JAMA Netw Open.* 2020;3(2):e1921150.
6. **Miranda C, Silva V, Capita R, et al.** Implications of antibiotics use during the COVID-19 pandemic: present and future. *J Antimicrob Chemother.* 2020;75(12):3413–3416.
7. **WHO.** Media statement: knowing the risks for COVID-19. March 3, 2020 [cited October 4, 2020]. <https://www.who.int/indonesia/news/detail/08-03-2020-knowing-the-risk-for-covid-19>. Accessed January 28, 2021.
8. **Malik UR, Atif N, Hashmi FK, et al.** Knowledge, attitude, and practices of healthcare professionals on COVID-19 and risk assessment to prevent the epidemic spread: a multicenter cross-sectional study from Punjab, Pakistan. *Int J Environ Res Public Health.* 2020;17(17):6395.
9. **Ventola CL.** The antibiotic resistance crisis: part 1: causes and threats. *P T.* 2015;40(4):277–283.
10. **Brink AJ, Messina AP, Feldman C, et al.** Antimicrobial stewardship across 47 South African hospitals: an implementation study. *Lancet Infect Dis.* 2016;16(9):1017–1025.
11. **Getahun H, Smith I, Trivedi K, et al.** Tackling antimicrobial resistance in the COVID-19 pandemic. *Bull World Health Organ.* 2020;98(7):442–442A.
12. **Butt MH, Ahmad A, Misbah S, et al.** Dengue fever and COVID-19 coinfection; a threat to public health for coepidemic in Pakistan. *J Med Virol.* 2021;93(2):671–672.